Keyword: Kenneth Frazier

A closer look at the Merck's new pricing plan reveals it really isn’t changing all that much, analysts say.

HHS Secretary Alex Azar pledged shame, anger and discount-minded Medicare drug plans to fight high prices.

Merck's Keytruda ginned up $1.46 billion in the first quarter, but analysts grilled CEO Ken Frazier about his plans to deliver new backup.

Merck’s Kenneth Frazier is breaking his silence about his decision last August to resign from the president's manufacturing council.

Does industry still fear the threat of pricing reform from the Trump Administration?

As the drug industry took heat in 2017 for "getting away with murder," among other criticisms, its lobbyists were busy behind the scenes.

Payer discounts are likely to grow even if midterm elections revive attacks on the industry—and investors should be worried about that, analysts say.

Merck & Co.'s top executive said Monday that pricing pressure isn't likely to get worse. But Eli Lilly CEO David Ricks begs to differ.

The good news about drug pricing pressure, according to Merck CEO Ken Frazier? It won't get much worse.

Congress has called on Merck CEO Ken Frazier to give full accounting on how badly affected its global manufacturing was by the Petya malware attack.